Answers are grounded in this paper and cite their sources.
A 70-year-old Caucasian man, resident in Liguria, Italy, presented with a complex clinical picture. His medical history was unremarkable. From 2001 to 2010, he spent 5 months each year in India. He had also travelled to Sri Lanka, Myanmar, Thailand and Nepal. In 2018, the patient noticed the onset of asymptomatic, diffuse erythematous plaques on the skin, but didn't seek care, considering them unimportant. In 2020, he developed recurrent edema of the left foot, associated with progressive hypoesthesia and paresthesia. Neurological assessment revealed ‘stocking-like’ superficial hypoesthesia up to the ankle on the left side, with no motor deficits, reduced deep tendon reflexes in the lower limbs, and bilateral hypopallesthesia. Laboratory tests detected previously undiagnosed diabetes mellitus. Therapy with metformin and diet was initiated, achieving good glycemic control by June 2024. Despite metabolic improvement, neurological symptoms worsened, with progressive paresthesias involving the right leg and both upper limbs. A 20-kg unintentional weight loss was also reported, raising concern for a paraneoplastic aetiology. Extensive investigations, including anti-neuronal and anti-myelin-associated glycoprotein antibodies, genetic testing for transthyretin amyloidosis, haematological evaluation, full-body CT scan, PET-CT, were all unremarkable. During the summer of 2024, the patient developed worsening rhinitis that was difficult to classify. In January 2025, the patient presented to the dermatologist with nodules and diffuse erythematous plaques on the trunk, limbs, face, and earlobes (Figure 1), along with hyperkeratotic and ulcerated lesions on palms and soles (Figure 2). A biopsy was performed on a hyperkeratotic lesion of the right palm (Figures 3 and 4). In March 2025, the patient was hospitalized. On physical examination, the patient presented with superficial hypoesthesia in the previously described skin lesions (Figures 1 and 2). No gross thickening of peripheral nerves was observed. However, he exhibited superficial hypoesthesia up to mid-thigh and mid-arm bilaterally. A skin smear test showed a bacillary index of 4+ at all sites tested (earlobes, elbows, knees, and right thigh lesion). Nasal smear was also positive (4+). Serological testing for anti-PGL-1 antibodies was strongly positive, with titers 40 times above the threshold. The skin biopsy demonstrated dermal infiltration by foamy histiocytes with a perivascular and interstitial distribution, the presence of a ‘grenz zone’ and no granulomas (Figure 3). Histological examination also shows invasion of the arrector pili muscle by the inflammatory infiltrate (Figure 4, indicated by black arrows). A diagnosis of lepromatous leprosy was made. Molecular testing for drug resistance (folP1, rpoB, gyrA genes) was performed. Fite-Faraco staining confirmed numerous acid-fast bacilli (Figure 5). The patient was started on WHO-recommended multidrug therapy. He showed general clinical improvement and was discharged in good condition after 2 weeks, although the sensorimotor polyneuropathy induced by leprosy persisted. All close contacts underwent clinical examination and anti-PGL-1 antibody testing, and an annual follow-up was scheduled for the following 5 years. Although the guidelines are not clear regarding the need for postexposure prophylaxis, we opted to administer a single dose of 600 mg rifampicin. Leprosy is a neglected tropical disease. [1] It is a chronic infectious disease caused by the acid-fast bacilli of the Mycobacterium leprae complex, which can be transmitted either directly or indirectly. [2] The incubation period is highly variable, but it can extend up to 30 years. [2] Leprosy predominantly affects the skin and peripheral nerves, and ocular involvement is often present. [3] If left untreated, it may result in progressive and permanent disabilities. [4] Diagnosis is primarily clinical and requires the presence of at least one of the following cardinal signs: a definite loss of sensation in a hypopigmented or reddish skin patch; thickened or enlarged peripheral nerves associated with sensory loss and/or muscle weakness; or microscopic detection of bacilli in a slit-skin smear. [4] In our patient, the characteristic skin lesions and neurological alterations should have raised suspicion of the diagnosis, even though it is a very rare disease in Italy. The patient likely acquired the infection during earlier travels in Southeast Asia, with symptoms emerging later due to age-related immune decline. Since the 2000s, the global incidence of leprosy has decreased, but it remains a significant health issue in many parts of the world. [5] In Western countries, the incidence is very low: in Italy, 203 new cases were reported between 1990 and 2019, and the majority have occurred in immigrants. [6] The rarity of leprosy in Italy has led to a decline in diagnostic awareness among healthcare professionals. The most recent national guidelines, published in 1996 [7], are now outdated. This lack of training contributes to delayed diagnosis, continued transmission, and missed opportunities for early treatment, as illustrated by our patient, who was diagnosed 7 years after symptom onset. Leprosy should be considered in patients with cutaneous lesions and sensory or motor deficits. A detailed travel history, particularly to endemic areas, is crucial. Increasing international travel and migration may influence leprosy epidemiology in Italy. Targeted training programs are essential for healthcare workers, including dermatologists, neurologists, and ophthalmologists. Rebecca Donadoni and Giulia Merlo contributed equally to the conception and drafting of the manuscript. Antonio Guadagno performed the histopathological analysis, interpreted the findings, and contributed to their integration into the report. Stefania Artioli and Corrado Cabona contributed to the diagnostic assessment. Rebecca Donadoni, Giulia Merlo and Gabriele Zanardi collected the clinical data. Claudia Micalizzi and Emanuele Cozzani reviewed and revised the content for accuracy and clarity, and ensured its scientific integrity. All authors critically revised the manuscript for important intellectual content and approved the final version. The authors have nothing to report. The patient described in this manuscript has given written informed consent for participation in the study and for the use of his de-identified, anonymized, aggregated data and case details (including photographs) for publication. Ethical Approval: not applicable. The authors declare no conflicts of interest. Data sharing is not applicable to this article, as no data sets were generated or analysed during the current study.
No takes yet. Share an insight, caveat, or question.
Donadoni et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: